These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25083569)

  • 1. Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs.
    Batista LA; Gobira PH; Viana TG; Aguiar DC; Moreira FA
    Behav Pharmacol; 2014 Sep; 25(5-6):425-33. PubMed ID: 25083569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
    Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
    Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
    Petrosino S; Di Marzo V
    Curr Opin Investig Drugs; 2010 Jan; 11(1):51-62. PubMed ID: 20047159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
    Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
    CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.
    Patel S; Hillard CJ
    J Pharmacol Exp Ther; 2006 Jul; 318(1):304-11. PubMed ID: 16569753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs--A practical view.
    Fowler CJ
    Eur Neuropsychopharmacol; 2015 Jun; 25(6):749-62. PubMed ID: 25791296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual FAAH/MAGL inhibitor JZL195 has enhanced effects on endocannabinoid transmission and motor behavior in rats as compared to those of the MAGL inhibitor JZL184.
    Seillier A; Dominguez Aguilar D; Giuffrida A
    Pharmacol Biochem Behav; 2014 Sep; 124():153-9. PubMed ID: 24911644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocannabinoid Hydrolase Inhibitors: Potential Novel Anxiolytic Drugs.
    Zhao H; Liu Y; Cai N; Liao X; Tang L; Wang Y
    Drug Des Devel Ther; 2024; 18():2143-2167. PubMed ID: 38882045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabinoids and anxiety.
    Moreira FA; Wotjak CT
    Curr Top Behav Neurosci; 2010; 2():429-50. PubMed ID: 21309120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors.
    Saario SM; Laitinen JT
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):287-93. PubMed ID: 17910610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocannabinoid system: An overview of its potential in current medical practice.
    Mouslech Z; Valla V
    Neuro Endocrinol Lett; 2009; 30(2):153-79. PubMed ID: 19675519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors.
    van Egmond N; Straub VM; van der Stelt M
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():441-463. PubMed ID: 32867595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake.
    Chicca A; Nicolussi S; Bartholomäus R; Blunder M; Aparisi Rey A; Petrucci V; Reynoso-Moreno IDC; Viveros-Paredes JM; Dalghi Gens M; Lutz B; Schiöth HB; Soeberdt M; Abels C; Charles RP; Altmann KH; Gertsch J
    Proc Natl Acad Sci U S A; 2017 Jun; 114(25):E5006-E5015. PubMed ID: 28584105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The endocannabinoid system: emotion, learning and addiction.
    Moreira FA; Lutz B
    Addict Biol; 2008 Jun; 13(2):196-212. PubMed ID: 18422832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias.
    Rodríguez-Cueto C; Benito C; Romero J; Hernández-Gálvez M; Gómez-Ruiz M; Fernández-Ruiz J
    Pathobiology; 2014; 81(3):149-59. PubMed ID: 24642775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocannabinoid metabolism and transport as targets to regulate intraocular pressure.
    Miller S; Daily L; Dharla V; Gertsch J; Malamas MS; Ojima I; Kaczocha M; Ogasawara D; Straiker A
    Exp Eye Res; 2020 Dec; 201():108266. PubMed ID: 32979397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1.
    Palumbo-Zerr K; Horn A; Distler A; Zerr P; Dees C; Beyer C; Selvi E; Cravatt BF; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2012 Dec; 71(12):2051-4. PubMed ID: 22915616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential application of endocannabinoid system agents in neuropsychiatric and neurodegenerative diseases-focusing on FAAH/MAGL inhibitors.
    Ren SY; Wang ZZ; Zhang Y; Chen NH
    Acta Pharmacol Sin; 2020 Oct; 41(10):1263-1271. PubMed ID: 32203086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential Therapeutic Value of a Novel FAAH Inhibitor for the Treatment of Anxiety.
    Marco EM; Rapino C; Caprioli A; Borsini F; Laviola G; Maccarrone M
    PLoS One; 2015; 10(9):e0137034. PubMed ID: 26360704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Functional role of the endocannabinoid system in emotional homeostasis].
    Marco EM; Viveros MP
    Rev Neurol; 2009 Jan 1-15; 48(1):20-6. PubMed ID: 19145562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.